GEHC Outpaces Peers Into Earnings as Analysts Race to Raise Targets

GE HealthCare Technologies gained 7% last week, more than three times the median move of its closest peers: STE, SYK, and ABT all rose between 2% and 3%, while BDX and ZBH added less than 2%. GEHC's short interest, at 4.2% of free float, sits broadly in line with the group, but the stock's outperformance on the week is the sharper divergence.

Analyst moves in the 24 hours before the print drove much of that gap. JP Morgan's Robbie Marcus raised his target from $70 to $80 while keeping a Neutral rating. Citigroup lifted from $71 to $79, also Neutral. RBC Capital went to $90 from $80, reiterating Outperform. Barclays moved to $95 from $85 with an Overweight. The consensus mean now stands at $86.80 against a close of $76.42, implying roughly 14% upside. Notably, these target raises followed a brief early-October period where both Citigroup and BTIG had trimmed numbers, a reversal in direction that coincides almost exactly with the stock's rally from around $66.

The bull-bear divide comes down to execution quality and geographic mix. Bulls point to a $23.9 billion backlog, a roughly half-recurring revenue model across services, pharmaceutical diagnostics, and digital solutions, and management's medium-term target of 17% to 20-plus percent operating margin. The Sofie Biosciences acquisition for $945 million adds a phase 3 radiopharmaceutical asset and is expected to be accretive in its first full year. Bears counter with China, where revenue mix fell from 15% in 2021 to 11% in 2025 and has been a consistent growth drag of 60 to 140 basis points per year. Hospital capital budget pressure and $250 million of tariff impact booked in 2025 are the other live concerns; the question is whether cost discipline is absorbing those headwinds or constraining the commercial engine.

Short positioning has been in flux but is no longer building. Bears pushed shares short from about 16.6 million on October 8 to a peak of 21.2 million on October 23, a 28% jump in two weeks. Since then, the position has unwound to 19.2 million, and the ORTEX short score has retreated to 42.8 from a peak of 45.8, consistent with tactical rather than structural bearishness. Borrow availability is extremely loose at 1,354% of outstanding short interest, and cost to borrow is just 0.44%. There is no friction preventing further short-selling, which makes the recent partial cover more a read on positioning sentiment than a supply constraint.

One institutional footnote worth watching: Dodge & Cox has grown its stake to 10.5% of the class, adding nearly 9.5 million shares in the quarter to September 30, making it by far the largest disclosed holder. The buyback programme has also picked up sharply, with shares repurchased in Q2 2026 running 136% above the prior year's quarter at 3.3 million shares, and buyback spend doubling to $200 million.

The Q3 print will test whether the backlog is converting to revenue at a pace that justifies both the week's rally and the cluster of analyst target upgrades.